CompletedPhase 1NCT03962062
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Studying Onchocerciasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medicines Development for Global Health
- Principal Investigator
- Nicholas O Opoku, MDUniversity of Health and Allied Sciences School of Public Health, Hohoe, Ghana
- Intervention
- Moxidectin(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 4-17 years · All sexes
- Timeline
- 2021 – 2022
Study locations (1)
- University of Health and Allied Services School of Public Health, Hohoe, Volta Region, Ghana
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03962062 on ClinicalTrials.govOther trials for Onchocerciasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06350851Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationBioaster
- ACTIVE NOT RECRUITINGPHASE2NCT05180461Emodepside Phase II Trial for Treatment of OnchocerciasisDrugs for Neglected Diseases
- ACTIVE NOT RECRUITINGPHASE3NCT03876262Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisMedicines Development for Global Health